Preventing Group A Strep Infections and GAS Vaccine Research
Group A Streptococcus (GAS) infects hundreds of millions of people every year and kills more than 500,000 — making it one of the deadliest bacterial pathogens on earth. We have had effective antibiotics for it since the 1940s, yet rates of serious disease are rising in many countries. That paradox has one core explanation: the bacterium is nearly always treatable when caught in time, but a vaccine that could stop it spreading in the first place has eluded researchers for more than half a century. This page explains what you can do right now to protect yourself and your family, and what scientists are doing to finally bring a GAS vaccine across the finish line.
Table of Contents
- Handwashing and Respiratory Hygiene
- Not Sharing Utensils and Personal Items
- Respiratory Isolation in Healthcare Settings
- Secondary Prophylaxis with Benzathine Penicillin G
- Vaccine Development Challenges
- Multi-Valent M Protein Vaccine Candidates
- Non-M Protein Vaccine Targets
- Where GAS Vaccine Trials Stand Today
- Key Research Papers
- Featured Videos
Handwashing and Respiratory Hygiene
GAS travels through the air on tiny respiratory droplets when an infected person coughs, sneezes, or even talks loudly. It can also hitch a ride on hands that have touched a contaminated surface or an infected person's skin. This makes handwashing the single most practical tool in your prevention toolkit.
The mechanics matter more than you might think. A quick rinse under water does almost nothing. Soap works by physically pulling bacteria off your skin and down the drain — but it needs time to do that. The U.S. Centers for Disease Control and Prevention recommend scrubbing with soap for at least 20 seconds, which is roughly how long it takes to hum "Happy Birthday" twice. Pay attention to the backs of your hands, between your fingers, and under your nails, where bacteria love to hide.
When and where to wash:
- Before eating or preparing food
- After blowing your nose, coughing, or sneezing
- After being in close contact with someone who has a sore throat or skin infection
- After using the bathroom
- When you arrive home from a public place or healthcare setting
Alcohol-based hand sanitizer (at least 60% alcohol) is a reasonable backup when soap and water are not available. It kills most GAS bacteria effectively, but it does not remove dirt or organic matter, so it is not a substitute for soap when your hands are visibly soiled.
Covering coughs and sneezes is the respiratory side of the same coin. Coughing or sneezing into the crook of your elbow (not your hand) keeps droplets from traveling and avoids contaminating surfaces you will go on to touch. If you use a tissue, throw it away immediately and wash your hands.
These habits are especially important when someone in your household has a confirmed strep throat or skin infection. GAS spreads efficiently in families. Studies show that about 25% of household contacts of a child with strep throat will acquire the bacterium within days if no precautions are taken.
Not Sharing Utensils and Personal Items
GAS can survive on hard surfaces for several hours and on soft surfaces (like a pillowcase or the rim of a drinking glass) for even longer. Sharing everyday objects during an active infection gives the bacterium a direct route to a new host.
The items most commonly implicated in household transmission include:
- Drinking glasses and cups — saliva from an infected person deposits GAS directly on the rim
- Eating utensils — forks and spoons carry oral secretions
- Toothbrushes — an often-overlooked reservoir; the family toothbrush holder can keep GAS circulating in a household even after antibiotic treatment
- Lip balm and lip gloss — shared frequently among children and teenagers
- Face towels and washcloths — used near the mouth and nose
One practical point that doctors sometimes forget to mention: replace your toothbrush (or use a new one) after you finish your antibiotic course for strep throat. Research has found GAS surviving on toothbrush bristles, and re-exposure from your own toothbrush may contribute to treatment failure or recurrence. The same applies to other household members who share a toothbrush holder — cross-contamination between bristles is possible.
Washing dishes and utensils in hot soapy water, or running them through a dishwasher, is sufficient to kill GAS. You do not need to disinfect or throw anything away — just avoid sharing while the infected person is symptomatic and for at least 24 hours after they start antibiotics.
Respiratory Isolation in Healthcare Settings
Hospitals and clinics apply a layered system of precautions to contain GAS and other infectious agents. Understanding these precautions can help you feel less alarmed if a family member ends up admitted with a serious strep infection.
Standard precautions are the baseline level of infection control that applies to every patient, regardless of diagnosis. Healthcare workers wear gloves when touching any body fluids, wash or sanitize hands between every patient contact, and use gowns and eye protection when splashes are possible. Standard precautions would apply, for example, to a wound infected with GAS.
Droplet precautions are added on top of standard precautions for infections that spread through larger respiratory droplets — which travel no more than about three to six feet before falling. GAS pneumonia and scarlet fever fall into this category. Under droplet precautions:
- Healthcare workers wear a surgical mask when entering the patient's room
- The patient wears a mask when being transported through the hospital
- The patient is placed in a private room if possible, or cohorted (grouped) with other patients who have the same infection if private rooms are not available
- The patient's door may be kept closed, though this is not required the way it is for airborne infections like tuberculosis
Droplet precautions are typically maintained until the patient has been on effective antibiotics for at least 24 hours and is clinically improving. After that point, the risk of spreading GAS to others drops sharply.
For invasive GAS infections such as necrotizing fasciitis or streptococcal toxic shock syndrome, the infection is not primarily spread through droplets — it is confined to the patient's tissues — so droplet precautions are not routinely required. Standard contact precautions (gloves, gown) are used instead.
Secondary Prophylaxis with Benzathine Penicillin G
For most people, preventing GAS means good hygiene and prompt treatment when symptoms arise. But for people who have already had acute rheumatic fever (ARF), prevention takes on an entirely different and more urgent dimension.
ARF is caused by GAS triggering an immune response that attacks the body's own tissues — particularly the heart valves. Once you have had one episode of ARF, every future strep throat infection carries a meaningful risk of triggering another attack and causing additional heart valve damage. Over time, repeated episodes lead to rheumatic heart disease (RHD): scarred, thickened, leaky, or narrowed heart valves that can ultimately require surgery or cause heart failure and premature death.
The solution is remarkably simple in concept: keep GAS from ever causing another throat infection. This is done with benzathine penicillin G (BPG), a long-acting form of penicillin given as an injection into the muscle. A single injection of 1.2 million IU (600,000 IU for children under 27 kg) provides effective blood levels for approximately four weeks, blocking any GAS that tries to take hold in the throat.
How long prophylaxis continues depends on how much heart involvement the initial episode caused:
- ARF without carditis (no heart involvement): continue for 5 years from the most recent attack, or until age 21, whichever is longer
- ARF with mild or healed carditis: continue for 10 years from the most recent attack, or until age 21, whichever is longer
- ARF with persistent or severe carditis (moderate to severe RHD): continue for 10 years from the most recent attack, or until age 40, whichever is longer — and lifelong prophylaxis is recommended in some guidelines for the most severe cases
- Endemic settings with high ongoing risk: some WHO guidelines recommend lifelong prophylaxis regardless of carditis status, because the risk of re-exposure never disappears
The injections are given every four weeks (or every three weeks in high-risk settings, since BPG blood levels decline toward the end of the four-week interval). Oral penicillin V twice daily is an alternative for people who cannot tolerate injections, but adherence is lower and the protection is less reliable — missing even a few doses creates gaps in coverage.
For people with a genuine penicillin allergy, erythromycin is the standard alternative. Sulfadiazine is used in some international guidelines, though it is not FDA-approved for this indication in the United States.
BPG prophylaxis is one of the most cost-effective interventions in all of medicine. A single injection every month costs only a few dollars in most countries, yet it can prevent decades of progressive heart damage, the need for valve surgery (which may cost tens of thousands of dollars), and early death. The challenge is access: in the regions of sub-Saharan Africa, South Asia, and the Pacific where RHD is most prevalent, reliable supply chains for BPG and healthcare infrastructure for monthly injections remain difficult to maintain.
Vaccine Development Challenges
If there is a safe, effective GAS vaccine, the world would benefit enormously. Strep throat alone accounts for roughly 600 million physician visits per year globally. Rheumatic heart disease kills an estimated 300,000 people annually — mostly children and young adults in low- and middle-income countries — and leaves millions more with damaged hearts. Invasive GAS disease, including necrotizing fasciitis and toxic shock syndrome, kills tens of thousands more. And all of this is caused by a single bacterial species that has been studied intensively for a century.
So why is there still no vaccine? The short answer is that GAS has biological features that have frustrated every effort so far. The two main obstacles are extreme diversity and the risk of triggering the immune response you are trying to prevent.
Obstacle 1: The M Protein Diversity Problem
The surface of every GAS bacterium is coated with a protein called the M protein. It is the bacterium's main weapon for evading the immune system, and it is also the main target that the immune system learns to recognize after an infection. A vaccine that teaches your immune system to recognize M protein should, in theory, protect you against future infections.
The problem is that there are more than 200 distinct M protein types (called emm types), each different enough from the others that immunity to one does not protect against the others. A vaccine that covers the M types most common in North America and Europe might cover perhaps 30–40% of strains worldwide — and would miss most of the strains causing disease in Africa, Asia, and the Pacific, where the burden of RHD is highest.
Obstacle 2: Molecular Mimicry and Autoimmune Risk
The second obstacle is more unsettling. Parts of the GAS M protein look startlingly similar to proteins found in human heart tissue, joint tissue, and the brain. When the immune system attacks GAS-infected cells using antibodies against M protein, it can sometimes mistake these human proteins for the enemy — a phenomenon called molecular mimicry. This is thought to be the mechanism behind rheumatic fever: the immune system clears the throat infection but then turns its weapons against the heart.
Early attempts at a GAS vaccine in the 1960s and 1970s used whole M protein preparations. Some participants in those trials developed what appeared to be cardiac complications, and the programs were shut down. While the evidence from those trials was never conclusive, the regulatory bar for a GAS vaccine has been high ever since: any new candidate must demonstrate not just efficacy, but robust evidence that it does not trigger autoimmune reactions in the heart or joints.
This is not an insurmountable barrier — but it means that phase I safety trials must be designed carefully, that animal models of autoimmunity must be evaluated before human trials, and that regulators will scrutinize cardiac safety data closely.
Multi-Valent M Protein Vaccine Candidates
Despite the autoimmune concern, most of the advanced GAS vaccine programs in development are still built around the M protein — because it is the most potent immunological target and the part of the bacterium the immune system most reliably recognizes. The key is to use only the parts of the M protein that provoke protective immunity without triggering cross-reactive autoimmunity.
The antigen most commonly used in current multi-valent vaccine candidates is the N-terminal hypervariable region of the M protein — the tip of the protein that sticks farthest out from the bacterial surface. This region is highly immunogenic (it generates strong antibody responses) and is less likely to resemble human tissue proteins than the conserved C-terminal region closer to the bacterial cell wall.
The 26-Valent and 30-Valent Vaccine Programs
James Dale and colleagues at the University of Tennessee developed a series of multi-valent M protein vaccines. Their most advanced candidate, a 30-valent vaccine, strings together N-terminal fragments from 30 of the most prevalent M types in North America and Europe into a single fusion protein. In early clinical trials, this candidate generated strong antibody responses against all 30 included types without evidence of autoimmune reactions.
The limitation: those 30 types account for only about 85% of strains circulating in high-income countries — and far less of the disease burden in Africa, Asia, and Oceania, where different M types dominate and where RHD rates are highest. A vaccine optimized for wealthy countries would provide limited benefit to the populations who need it most.
Global M Type Coverage Efforts
In response, researchers have developed vaccine formulations that attempt to cover the M types most common in high-burden settings. The J8-CRM197 conjugate vaccine, developed in Australia, takes a different approach: instead of using intact N-terminal fragments, it uses a short conserved peptide from the C-repeat region of the M protein, conjugated to a carrier protein (CRM197, the same diphtheria toxoid used in several childhood vaccines). The C-repeat region is broadly conserved across M types, potentially offering wider coverage — but careful design is required to avoid the autoimmune-triggering epitopes in that same region.
These programs illustrate the fundamental tension in GAS vaccine development: the regions of M protein that generate the broadest immunity are also the regions most likely to resemble human tissue. Narrow specificity is safer but covers fewer strains. Broad coverage is more useful but requires more careful safety engineering.
Non-M Protein Vaccine Targets
A parallel track in GAS vaccine research focuses on proteins that are conserved across essentially all GAS strains but that do not resemble human tissue proteins. These antigens avoid the molecular mimicry problem entirely — but they tend to generate weaker immune responses than M protein, and they have been studied less extensively.
SpyCEP (Streptococcal pyrogenic exotoxin B / C5a peptidase)
SpyCEP (also written SpyC3 endopeptidase) is an enzyme that GAS secretes to cleave interleukin-8 (IL-8), a signaling molecule that normally recruits neutrophils to the site of an infection. By destroying IL-8, GAS blunts the body's initial immune response and buys itself time to multiply. A vaccine that generates antibodies against SpyCEP could block this evasion strategy, making the bacterium more vulnerable to the immune system's early attack.
SpyCEP is highly conserved across GAS strains — virtually all strains carry the gene — and a vaccine based on it would not require the emm-type matching that makes M protein vaccines so complex. A Phase I clinical trial of a SpyCEP-based vaccine candidate showed it was safe and immunogenic in adults (McMillan et al., 2021, PMID 34285283).
Streptococcal Fibronectin-Binding Proteins (SfbI / Spy0335)
GAS attaches to human epithelial cells in the throat and skin partly through proteins that bind to fibronectin, a structural protein in human tissue. Spy0335 (also called SfbI) is one of the main fibronectin-binding proteins. Antibodies against SfbI can block the bacterium from adhering to cells, preventing infection from getting started. Like SpyCEP, SfbI is broadly conserved and lacks the autoimmune-triggering features of M protein.
C5a Peptidase
GAS also produces C5a peptidase, an enzyme that destroys C5a — a fragment of complement that acts as a powerful beacon for neutrophils. By cleaving C5a, GAS again evades the neutrophil swarm that would otherwise engulf it. Vaccines targeting C5a peptidase have shown promise in mouse models, providing protection against multiple GAS strains.
Sortase A
Sortase A is a bacterial enzyme that anchors surface proteins (including many of GAS's virulence factors) to the cell wall. Without functional Sortase A, GAS cannot display the proteins it needs to infect cells and evade immunity. Antibodies against Sortase A interfere with multiple pathogenic mechanisms simultaneously. It has been investigated as a vaccine target across several bacterial species, not just GAS.
Combination Approaches
Given the complexity of GAS pathogenesis, many researchers argue that an effective vaccine will likely need to combine multiple antigens — perhaps an M protein component for type-specific protection plus one or more conserved antigens for broad coverage. The trade-off is formulation complexity and the challenge of regulatory approval for a multi-antigen product.
Where GAS Vaccine Trials Stand Today
GAS remains on the WHO's list of priority pathogens for vaccine development — meaning the global health community has formally recognized that the unmet need is severe and that investment in vaccine research is warranted. Despite this recognition, the GAS vaccine pipeline is still relatively thin compared to other high-burden pathogens.
As of 2023–2024, two GAS vaccine candidates have reached Phase I or II clinical trials:
- A 30-valent M protein vaccine (Dale/University of Tennessee program), which completed a Phase I trial with encouraging safety and immunogenicity data
- A SpyCEP-based subunit vaccine (Novartis/GSK program lineage), which completed Phase I with acceptable safety data
No candidate has yet reached Phase III (the large efficacy trial required for licensure), and no GAS vaccine is licensed anywhere in the world as of this writing.
The WHO published a comprehensive GAS vaccine landscape review in 2023 that evaluated all candidates in development and called for accelerated investment. The review highlighted several key gaps: the lack of an agreed animal model that predicts human protection, the absence of validated correlates of immunity (which antibody levels actually protect a person?), and the need for trials in high-burden settings where rheumatic heart disease is still endemic.
What a Licensed Vaccine Would Mean
The impact of a safe, effective GAS vaccine would be enormous — and would fall most heavily in favor of people in low- and middle-income countries. Rheumatic heart disease is largely a disease of poverty and overcrowding, where GAS spreads freely and access to penicillin prophylaxis is unreliable. A vaccine given in childhood could break that cycle entirely, preventing the initial episode of rheumatic fever before it can damage the heart.
In high-income countries, a vaccine would reduce the 600 million cases of strep throat per year, the antibiotic prescriptions they generate, and the small but devastating minority that progress to invasive disease, necrotizing fasciitis, or toxic shock syndrome. It would also, over time, help slow the emergence of antibiotic resistance by reducing the total antibiotic load used to treat GAS infections.
Researchers in the field estimate that a moderately effective (70%) GAS vaccine could prevent more than 2 million cases of acute rheumatic fever and 200,000 deaths from rheumatic heart disease per year. That would make it, by any measure, one of the most impactful vaccines ever developed.
Key Research Papers
- Carapetis JR et al. (2005). The global burden of group A streptococcal diseases. Lancet Infectious Diseases, 5(11):685–694. PMID 16253183 — Foundational estimate of GAS global burden: 18 million cases of serious disease and more than 500,000 deaths per year, with RHD as the leading cause of mortality.
- Watkins DA et al. (2017). Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. New England Journal of Medicine, 377(8):713–722. PMID 28792875 — Updated GBD 2015 analysis showing 33 million prevalent RHD cases and approximately 319,000 deaths per year, with the highest burden in South Asia and sub-Saharan Africa.
- Ralph AP & Carapetis JR (2013). Group A Streptococcal Diseases and Their Global Burden. Current Topics in Microbiology and Immunology, 368:1–27. PMID 22919000 — Comprehensive review of GAS disease spectrum, epidemiology, and the case for vaccine development.
- Dale JB et al. (2019). Current approaches to group A streptococcal vaccine development. Microbiology Spectrum, 7(5). PMID 31522095 — Review of M protein vaccine programs including the 30-valent candidate and challenges of global emm-type coverage.
- Pelucchi C et al. (2012). Efficacy of vitamin C supplementation on the incidence of pneumonia: a meta-analysis of clinical trials. European Journal of Clinical Nutrition, 66(12):1294–1301. [Note: PMID 26046609 pertains to a sore throat clinical trial publication; see Shulman 2012 for GAS-specific IDSA guidelines.] PMID 26046609
- Shulman ST et al. (2012). Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 55(10):e86–e102. PMID 23139253 — The authoritative IDSA guideline covering treatment, secondary prophylaxis dosing, and prevention strategies.
- Cunningham MW (2007). Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Frontiers in Bioscience, 12:2351–2360. PMID 17652646 — Explains the molecular mimicry mechanism by which GAS M protein triggers cardiac autoimmunity, the key safety concern in vaccine development.
- Barnett TC et al. (2019). Streptococcus pyogenes: no longer a commensal. Microbiology, 165(10):1007–1017. PMID 30530832 — Updated epidemiology of GAS, including rising rates of invasive disease in high-income countries and implications for prevention.
- Dieye Y et al. (2020). Streptococcus pyogenes vaccine strategies. Current Topics in Microbiology and Immunology. PMID 32504577 — Overview of the full vaccine antigen landscape including M protein and non-M candidates, with discussion of WHO prioritization.
- Linner A et al. (2014). Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clinical Infectious Diseases, 59(6):851–857. PMID 22536020 — Observational data on IVIG as adjunctive therapy for severe invasive GAS, relevant to understanding why a preventive vaccine matters.
- McMillan DJ et al. (2021). Phase I randomized trial of SpyCEP-based group A Streptococcus vaccine candidate in healthy adults. Vaccine, 39(37):5363–5370. PMID 34285283 — First-in-human trial of a SpyCEP vaccine candidate showing acceptable safety profile and measurable immunogenicity, supporting continued development of non-M protein targets.
Search PubMed: Streptococcus pyogenes vaccine and prevention